Table 4.

Ongoing Multicenter Phase III Clinical Trials Utilizing Antiangiogenic Agents in the Adjuvant Setting

Trial Sponsor/Number	Official Title	Phase
HER2-Positive
NSABP B-44-I	BETH Study: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab	III
HER2-Negative
ECOG 5103	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer	III
NSABP B-46-I	A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	III
Dana Farber 09-134	ABCDE: A Phase III Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer	III
Triple-Negative Tumors
Hoffmann-La Roche BO20289	An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer	III

Abbreviations: ECOG = Eastern Cooperative Oncology Group; NSABP = National Surgical Adjuvant Breast and Bowel Project